冠心病患者高敏C-反应蛋白、血清脂蛋白（α）与低密度脂蛋白C的测定

目的：探讨冠心病患者高敏C-反应蛋白、血清脂蛋白陋）与低密度脂蛋白的变化及其临床意义。方法：检测冠心病患者血清高敏C-反应蛋白（hsCRP）、血清脂蛋白㈥[LP（α）]、低密度脂蛋白C（LDL-C），同步测定正常人群作为对照组。结果：冠心病患者血清hsCRP、LP（α）、LDL—C水平分别为（2．82±0．96）、（278．16±78．64）和（2．85±0．82）mmol／L，与对照组比较有非常显著性差异（P〈0．01），且hsCRP、LP（α）差异更为显著。结论：冠心病的发生与患者血清LP（α）的浓度密切相关，hsCRP的预示价值也日益显现，建议临床对冠心病患者行hsCRP、LP（α）定量检测，以推动冠心病的预防和诊治。

Detection of hsCRP, LP (α) and LDL-C in the patients with coronary heart disease

Objective： To investigate the changes of hsCRP, Lipoproteln（α）[LP（α）] and LDL-C in the patients with coronary heart disease（CHD）. Methods： hsCRP, LP（α） and LDL-C in the serum of patients with CHD were detected. Results： hsCRP, LP（α） and LDL-C in the serum of patients with CHD were （2.82±0.96）, （278.16±78.64） and （2.98±0.82） mmol/L respectively. Compared with the control normal group, the levels of hsCRP, LP （α） and LDL-C significantly increased （P〈 0.01）, hsCRP and LP（α） showed a more considerable difference. Conclusion： CHD occurrence is associated with the levels of hsCRP, LP（α） and LDL-C in the serum of patients. It is suggested that hsCRP and LP（α） should be detected in the patients with CHD to promote the prevention and diagnosis of CHD.